About: Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives
Creator	Samal, Sweety Kumar, Rajesh Ahmed, Shubbir Parray, Hilal Shrivastava, Tripti Shukla, Shivangi
Source	Elsevier; Medline; PMC
abstract	The advancements in technology and manufacturing processes have allowed the development of new derivatives, biosimilar or advanced improved versions for approved antibodies each year for treatment regimen. There are more than 700 antibody-based molecules that are in different stages of phase I/II/ III clinical trials targeting new unique targets. To date, approximately more than 80 monoclonal antibodies (mAbs) have been approved. A total of 7 novel antibody therapeutics had been granted the first approval either in the United States or European Union in the year 2019, representing approximately 20% of the total number of approved drugs. Most of these licenced mAbs or their derivatives are either of hybridoma origin or their improvised engineered versions. Even with the recent development of high throughput mAb generation technologies, hybridoma is the most favoured method due to its indigenous nature to preserve natural cognate antibody pairing information and preserves innate functions of immune cells. The recent advent of antibody engineering technology has superseded the species level barriers and has shown success in isolation of hybridoma across phylogenetically distinct species. This has led to the isolation of monoclonal antibodies against human targets that are conserved and non-immunogenic in the rodent. In this review, we have discussed in detail about hybridoma technology, its expansion towards different animal species, the importance of antibodies isolated from different animal sources that are useful in biological applications, advantages, and limitations. This review also summarizes the challenges and recent progress associated with hybridoma development, and how it has been overcome in these years to provide new insights for the isolation of mAbs.
has issue date	2020-05-27(xsd:dateTime)
bibo:doi	10.1016/j.intimp.2020.106639
bibo:pmid	32473573
has license	no-cc
sha1sum (hex)	49209d678a211feb1ce887fce40373b6b2b7f6dd
schema:url	https://doi.org/10.1016/j.intimp.2020.106639
resource representing a document's title	Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives
has PubMed Central identifier	PMC7255167
has PubMed identifier	32473573
schema:publication	Int Immunopharmacol
resource representing a document's body	covid:49209d678a211feb1ce887fce40373b6b2b7f6dd#body_text
is schema:about of	named entity 'targets' named entity 'innate' named entity 'antibodies' named entity 'antibody' named entity 'preserves' named entity 'mAbs' named entity 'monoclonal antibodies' named entity 'This' named entity 'derivatives' named entity 'development' named entity 'summarizes' named entity 'nature' named entity 'technologies' named entity 'technology' named entity 'mAb' named entity 'indigenous' named entity 'high' named entity 'clinical trials' named entity 'manufacturing' named entity 'immune cells' named entity 'cognate' named entity 'antibodies' named entity 'hybridoma' named entity 'animal species' named entity 'monoclonal antibodies' named entity 'antibody engineering' named entity 'immunogenic' named entity 'hybridoma' named entity 'subcloning' named entity 'immunogenic' named entity 'cell line' named entity 'chicken' named entity 'hybridoma technology' named entity 'transformation efficiency' named entity 'glycoproteins' named entity 'antibodies' named entity 'Helicobacter pylori' named entity 'antibodies' named entity 'hybridoma technology' named entity 'single cells' named entity 'constant regions' named entity 'CpG' named entity 'rabies virus' named entity 'hybridoma' named entity 'cell line' named entity 'antibodies' named entity 'mAbs' named entity 'OKT3' named entity 'immunoglobulins' named entity 'homology' named entity 'animal species' named entity 'antibody response' named entity 'antigens' named entity 'antigen' named entity 'immunization' named entity 'rodent' named entity 'mAb' named entity 'immunogenic' named entity 'protein' named entity 'somatic' named entity 'immune response' named entity 'antibodies' named entity 'mAb' named entity 'biological functions' named entity 'light chains' named entity 'therapeutic agents' named entity 'chemical compound' named entity 'clones' named entity 'disease burden' named entity 'biologics' named entity 'antibodies' named entity 'egg yolk' named entity 'spleen' named entity 'rodent' named entity 'deoxynucleotide' named entity 'cell lines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software